Levomepromazine

What is levomepromazine?

First generation ‘typical’ antipsychotics such as levomepromazine are an older class of antipsychotic than second generation ‘atypical’ antipsychotics. They are used primarily to treat positive symptoms including the experiences of perceptual abnormalities (hallucinations) and fixed, false, irrational beliefs (delusions). First generation antipsychotics may cause side effects which can differ depending on which antipsychotic is being administered and on individual differences in reaction to the drug. Reactions may include dyskinesias such as repetitive, involuntary, and purposeless body or facial movements, Parkinsonism (cogwheel muscle rigidity, pill-rolling tremor and reduced or slowed movements), akathisia (motor restlessness, especially in the legs, and resembling agitation) and dystonias such as muscle contractions causing unusual twisting of parts of the body, most often in the neck. These effects are caused by the dopamine receptor antagonist action of these drugs.

What is the evidence for levomepromazine?

Moderate to low quality evidence suggests levomepromazine may cause less extrapyramidal symptoms than haloperidol. Low quality evidence is unable to determine differences between levomepromazine and other antipsychotic medications for other adverse effects. Low quality evidence is unable to determine any benefit of levomepromazine over chlorpromazine or risperidone.

November 2019

Last updated at: 3:48 am, 13th November 2019
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.